Cost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan
Wei-Ling Lee, Wan-Hsuan Chou, Wei-Pin Chang, Tsung-Wei Chang, Chun-Nan Kuo, Wei-Chiao Chang · 2024
Read Cost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan by Wei-Ling Lee, Wan-Hsuan Chou, Wei-Pin Chang, Tsung-Wei Chang, Chun-Nan Kuo, Wei-Chiao Chang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11698590.txt.
Description
Wei-Ling Lee and co-authors weighed the cost and benefit of a lung cancer drug mix in Taiwan in two thousand twenty-four. The mix pairs pembrolizumab with chemotherapy as first treatment for metastatic nonsquamous non-small cell lung cancer. They judged it from the view of Taiwan's public payer.
Their model ran ten years using survival data from a large trial. The mix gained zero point eight nine quality-adjusted life years at extra cost, giving a cost per gain below the set threshold. Gains were larger for patients whose tumors scored high on a marker called PD-L1. The authors call the mix cost-effective for this use in Taiwan.
Catalog record
| CREATOR | Wei-Ling Lee, Wan-Hsuan Chou, Wei-Pin Chang, Tsung-Wei Chang, Chun-Nan Kuo, Wei-Chiao Chang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |